Beam Appoints Commercial Veteran Eric Foster Amid Expansion Plans
Beam Therapeutics Inc., a biotechnology company developing precision genetic medicines through base editing, has appointed Eric Foster as its chief commercial officer. This move comes at an important moment for the company as it advances multiple product candidates across its hematology and genetic disease franchises toward potential launches.
Foster brings more than 25 years of commercial leadership experience to Beam, including stints at Horizon Therapeutics and Amgen after the latter acquired Horizon in October 2023. He has led operations for franchises that represented $2.75 billion in net sales revenue.
Beam's CEO, John Evans, praised Foster, saying he is an 'exceptional biopharmaceutical leader' with a proven track record of building high-performing commercial organizations in specialty and rare disease markets.